Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2024Annals of the Rheumatic Diseases

Pos0824 Artificial Intelligence (Deep Neural Network Analysis) as a Skin Outcome: Results of an Open-Label Belumosudil Trial in Patients With Diffuse Cutaneous Systemic Sclerosis

View Full Paper
Ask AI
Bookmark
Share

Authors

BGBurcu GunesDublin City UniversityLCLucy Duran CamachoYale UniversitySCShawn E. CowperYale University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Gunes et al. (2024) studied this question.

synapsesocial.com/papers/68e671b1b6db6435875fbb8fhttps://doi.org/10.1136/annrheumdis-2024-eular.2892
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1AB1142 DERMAL CELLULAR SENESCENCE AND ENDOTHELIAL-TO-MESENCHYMAL TRANSITION IN PATIENTS WITH SYSTEMIC SCLEROSIS TREATED WITH CYCLOPHOSPHAMIDE OR AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION2024
  2. 2OP0144 MULTIPLE SPATIAL PROTEOMICS TO DEFINE ENDOTHELIAL CELL PHENOTYPES AND ALTERATIONS OF THE VASCULAR NICHE IN SSc2024
  3. 3P139 A composite biomarker score to predict modified Rodnan skin score in systemic sclerosis: insight from Autologous Stem Cell Transplantation International Scleroderma Trial2026
  4. 4AB1173 CLINICAL CORRELATES OF PHYSICAL AND MENTAL HEALTH IN EARLY SYSTEMIC SCLEROSIS: BASELINE RESULTS FROM THE COLLABORATIVE NATIONAL QUALITY AND EFFICACY (CONQUER) REGISTRY USING THE PATIENT-REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS)-V292024
  5. 5P134 Developing a potential composite pharmacodynamic serum marker of skin severity in systemic sclerosis2024